吡柔比星不同膀胱灌注方法预防膀胱癌术后复发及不良反应的临床研究

Clinical Study of Intravesical Instillation of Pirarubicin by Two Methods on Preventing Recurrence of Bladder Cancer and Adverse Reaction

关键词:  浅表性膀胱癌  膀胱灌注  吡柔比星

Key words:  superficial bladder cancer  intravesical  pirarubicin

摘要:

目的 比较吡柔比星(THP)两种膀胱内灌注方法预防浅表性膀胱癌术后复发的有效性及安全性。方法 将80例经尿道膀胱癌电切术后浅表性膀胱癌患者随机分为2组，均于术后1周开始灌注，每次THP灌注剂量40 mg，每周灌注1次，连续8周，再改为每月灌注1次，至术后1年。灌注前实验组THP用蒸馏水80 mL稀释，对照组THP用蒸馏水40 mL稀释。结果 全部病例均获随访，时间为2年，2组复发率比较差异无统计学意义(P>0.05)，不良反应发生率实验组显著低于对照组(P<0.05)。结论 THP 40 mg+蒸馏水80 mL膀胱灌注方法可以明显降低肿瘤患者术后吡柔比星膀胱灌注的不良反应，值得推荐。

Abstract:

OBJECTIVE To compare the effect and safety of intravesical instillation of pirarubicin by two methods on preventing recurrence of superficial bladder cancer. METHODS All of 80 cases with bladder cancer after transurethral bladder tumor resection (TUR-BT) were divided into two groups in random. All cases accepted intravesical instillation of pirarubicin 40 mg in one week after operation, once a week for 8 weeks, then once a month for 1 year. The test group used THP 40 mg+ distilled water 80 mL, the control group used THP 40 mg+distilled water 40 mL. RESULTS All cases were followed-up 2 years after operation, the recurrence rate was no statistical significance between two groups(P>0.05), but the incidence rates of the adverse reaction in test group was significantly lower than control group(P<0.05). CONCLUSION Intravesical instillation of THP 40 mg+distilled water 80 mL can obviously reduce the adverse reaction, and it is worth recommending.